Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.

Abstract: Disclosed are a blockchain system and a consensus method for use in a miner node in a blockchain system. A specific embodiment of the method includes: acquiring a lower-limit accumulative unused duration; executing, in a trusted execution environment associated with the miner node, a bookkeeping right determination operation including: determining a current accumulative unused duration for the miner node; determining whether the current accumulative unused duration is more than the lower-limit accumulative unused duration; and, in response to the determination that the current accumulative unused duration is more than the lower-limit accumulative unused duration, determining that the miner node has won a bookkeeping right, and updating the current accumulative unused duration with a difference between the current accumulative unused duration and the lower-limit accumulative unused duration. This embodiment allows for reduced electric power consumption in a blockchain system.

Abstract: Various solutions for on-off keying (OOK) signal generation with respect to reader apparatus and an Internet of Things (IoT) device are described. A reader apparatus may generate an OOK signal with an orthogonal frequency-division multiplexing (OFDM) waveform, wherein a start of an OOK signal transmission is aligned with a boundary of a symbol of the OFDM waveform. The reader apparatus may transmit the OOK signal to an IoT device.

Abstract: A nonstick pan includes a pan body, where an inner surface of the pan body is provided with protruding dots; the protruding dots include a central protruding dot and surrounding protruding dots; the central protruding dot is located at a center of the inner surface of the pan body and surrounded by protruding dot rings that are distributed from inside to outside around the central protruding dot; the protruding dot ring includes a plurality of surrounding protruding dots separated from each other; the central protruding dot and the surrounding protruding dots have a protrusion height of H; concave portions are formed between the central protruding dot and the surrounding protruding dot and between the surrounding protruding dots on the inner surface of the pan body; and a nonstick layer is provided on the concave portions on the inner surface of the pan body.

Abstract: Embodiments of the instant disclosure relate to novel antiviral compositions and methods for treating viral infections. In accordance with these embodiments, antiviral compositions can include at least one mRNA encoding for a TRIM7 protein encapsulated into a lipid nanoparticle (LNP). In other embodiments, methods of making antiviral compositions are disclosed as well as methods of administering a composition having at least one mRNA encoding for a TRIM7 protein encapsulated into LNP into a subject.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: In an aspect of the disclosure, a method, a computer-readable medium, and an apparatus are provided. The apparatus may be a first UE. The first UE transmits a plurality of reference signals (RSs) using a plurality of transmission beams on a sidelink. The first UE receives, from a second UE, a beam report carried on a Physical Sidelink Feedback Channel (PSFCH). The beam report indicates beam qualities generated by the second UE based on measurements of the plurality of RSs. The first UE selects a transmission beam and a reception beam based on the beam qualities. The first UE establishes a sidelink communication with the second UE using the selected transmission beam and the selected reception beam on the sidelink.

Abstract: In an aspect of the disclosure, a method, a computer-readable medium, and an apparatus are provided. The apparatus may be a UE. The UE transmits a plurality of reference signals (RSs) using a plurality of transmission beams on a sidelink. The UE receives a beam report from a second UE. The beam report indicates a selected transmission beam from the plurality of transmission beams. The beam report also indicates a selected reception beam of the second UE. The selected transmission beam and the selected reception beam are based on measurements of the transmitted RSs. The UE establishes a sidelink communication with the second UE using the selected transmission beam and the selected reception beam on the sidelink.

Abstract: In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.

Abstract: Embodiments of the instant disclosure relate to novel antiviral compositions and methods for treating viral infections. In accordance with these embodiments, antiviral compositions can include at least one mRNA encoding for a TRIM7 protein encapsulated into a lipid nanoparticle (LNP). In other embodiments, methods of making antiviral compositions are disclosed as well as methods of administering a composition having at least one mRNA encoding for a TRIM7 protein encapsulated into LNP into a subject.

Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: A nonstick cooking utensil with a pure inorganic structural layer and a manufacturing method thereof are provided. The cooking utensil includes a base layer and a pure inorganic structural layer, where the pure inorganic structural layer is formed by spraying inorganic particles on an inner surface of the base layer; the inorganic particles in the pure inorganic structural layer form a connected pore structure; the pure inorganic structural layer includes at least three inorganic structural sub-layers; the at least three inorganic structural sub-layers are sequentially stacked on the inner surface of the base layer according to sizes of the inorganic particles; the inorganic particles in the inorganic structural sub-layer adjacent to the base layer have a largest size; and in a direction away from the base layer, the sizes of the inorganic particles in the multiple inorganic structural sub-layers decrease sequentially.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: Described herein are compositions, kits, and methods for potent delivery to a ceil of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. Tire lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: A UE obtains a channel occupancy time (COT) for a set of resources on a sidelink (SL) in an unlicensed spectrum through a channel access procedure. The UE determines whether a frequency division multiplexing (FDM) transmission scheme is utilized for a SL transmission on the sidelink in the COT. The UE selects a cyclic prefix extension (CPE) starting position prior to an initial symbol containing the SL transmission. The UE selects the default CPE starting position as the CPE starting position when the FDM transmission scheme is utilized. The UE randomly selects the CPE starting position from a subset of a set of all candidate CPE starting positions based on an L1 priority of the SL transmission when the FDM transmission scheme is not utilized. The UE transmits a CPE at the selected CPE starting position and performs the SL transmission after the CPE transmission.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: In an aspect of the disclosure, a method, a computer-readable medium, and an apparatus are provided. The apparatus may be a UE. The UE obtains a number (N) of transmissions of a sidelink synchronization signal block (S-SSB) with repetitions in a frequency domain. The UE obtains a gap in the frequency domain between two adjacent transmissions of the N transmissions. The UE maps the N S-SSBs into N sets of resources in which two adjacent sets are separated by the gap. The N sets of resources overlap in time domain. The UE performs the N transmissions of the S-SSB using the N sets of resources.

Abstract: Apparatus and methods are provided for sidelink (SL) transmission in SL unlicensed frequency bands (SL-U). In one novel aspect, one and/or multiple starting symbols within a slot is supported for SL-U to start a transmission. In one embodiment, the physical sidelink control channel (PSCCH) is configured to be transmitted on each starting symbol within a slot. In another embodiment, only physical sidelink shared channel (PSSCH) is transmitted on the starting symbols other than the first starting symbol within a slot. In one novel aspect, PSCCH is transmitted within one sub-channel. In one embodiment, the PSCCH is transmitted on a fixed subchannel of each RB set of the occupied BWP. In another embodiment, the PSCCH is transmitted on a fixed subchannel of one preconfigured RB set. In another novel aspect, the UE sets the CAPC value to be one for the physical sidelink feedback channel (PSFCH).